Cancer Treatment Company Anchiano Therapeutics Wants to List on Nasdaq
The company formerly known as BioCanCell submitted a prospectus to the SEC on Monday, with Oppenheimer & Co. as the sole underwriter
Founded in 2004 and based in Jerusalem and Cambridge, Massachusetts, clinical-stage Anchiano develops gene therapies for cancer, with a special focus on bladder cancer. The company announced its intention to delist from the Tel Aviv exchange in 2017 as part of a $22.8 million investment deal but the move was blocked by shareholders. To weaken opposition, the company issued 5.9 million new shares in April 2018.